tiprankstipranks

Scott L Burrows Insider Profile

4 Followers
Scott L Burrows, CFO at Arcutis Biotherapeutics, holds 116.42K shares in Spyre Therapeutics (Ticker: SYRE), holds 59.12K shares in Arcutis Biotherapeutics (Ticker: ARQT). Most recently, Scott L Burrows Sold ― shares of Spyre Therapeutics on Sep 05, 2024 for an estimated value of 522.02K.
tipranks
Scott L Burrows

Scott L Burrows
Arcutis Biotherapeutics (ARQT)
CFO

Not Ranked
Scott L Burrows has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$4M
84.18%
15.82%
A breakdown of Scott L Burrows's holdings

Insider Roles

Spyre Therapeutics
(SYRE)
CFO
Arcutis Biotherapeutics
(ARQT)
CFO
Roles that Scott L Burrows holds in companies

Most Profitable Insider Trade

Stock:
Spyre Therapeutics
(SYRE)
Rating:Informative Sell
Date:Sep 05, 2024 - Today
Return:-41.10%
The most profitable trade made by Scott L Burrows

Scott L Burrows's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Arcutis Biotherapeutics
Mar 08, 2023
CFO
Uninformative Sell
4.44K
$601.79K
Spyre Therapeutics
Sep 05, 2024
CFO
Informative Sell
522.02K
$3.20M
List of latest transactions for each holding click on a transaction to see Scott L Burrows's performance on stock

Scott L Burrows insider profile FAQ

What is the percentage of profitable transactions made by Scott L Burrows?
The percentage of profitable transactions made by Scott L Burrows is ―.
    What is the average return per transaction made by Scott L Burrows?
    The average return per transaction made by Scott L Burrows is ―.
      What stocks does Scott L Burrows hold?
      Scott L Burrows holds: ARQT, SYRE stocks.
        What was Scott L Burrows’s latest transaction?
        Scott L Burrows latest transaction was an Informative Sell of $522.02K.
          What was Scott L Burrows's most profitable transaction?
          Scott L Burrows’s most profitable transaction was an Informative Sell of SYRE stock on September 5, 2024. The return on the trade was -41.10%.
            What is Scott L Burrows's role in Arcutis Biotherapeutics?
            Scott L Burrows's role in Arcutis Biotherapeutics is CFO.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.